Article
Biochemistry & Molecular Biology
Qiurong Yang, Maoye Wang, Jing Xu, Dan Yu, Yixin Li, Yanke Chen, Xiaoxin Zhang, Jiahui Zhang, Jianmei Gu, Xu Zhang
Summary: In this study, a new lncRNA (LINC02159) was identified as upregulated in tumor tissues and serum of NSCLC patients. Knockdown of LINC02159 inhibited NSCLC cell proliferation, migration, and invasion, while overexpression led to the opposite effect. It was found that LINC02159 enhanced the stability of YAP1 mRNA through m(5)C modification by binding to ALYREF, resulting in the activation of Hippo and β-catenin signaling pathways. The findings suggest that LINC02159 plays an oncogenic role in NSCLC and has potential as a diagnostic marker and therapeutic target for the disease.
Article
Cell Biology
Huafeng Liu, Liting Zhong, Yanjun Lu, Xuewen Liu, Jiawang Wei, Yuhai Ding, Huiling Huang, Qihong Nie, Xiaohong Liao
Summary: This study reveals the mechanism of action of deubiquitylase OTUD1 in suppressing chemoresistance in non-small cell lung cancer (NSCLC). The results show that upregulation of OTUD1 increases the sensitivity of NSCLC cells to erlotinib by inhibiting the nuclear translocation of YAP1 and inactivating its downstream signals SOX9/SPP1.
CELL DEATH DISCOVERY
(2022)
Article
Cell Biology
Peixin Chen, Chenglong Sun, Hao Wang, Wencheng Zhao, Yan Wu, Haoyue Guo, Caicun Zhou, Yayi He
Summary: A study found that different molecular subtypes of small cell lung cancer (SCLC) have varying effects on the efficacy of immunotherapy, tumor microenvironment traits, and prognosis. Specifically, the SCLC-Y subtype with high YAP1 expression showed the worst clinical outcomes, with high PD-L1 expression and immune dysfunction, suggesting that YAP1 can further suppress immune response, leading to immune evasion.
CELL DEATH & DISEASE
(2023)
Article
Pharmacology & Pharmacy
Fang Li, Chengqiong Mao, Stacy Yeh, Yao Sun, Junbo Xin, Qin Shi, Xin Ming
Summary: This study demonstrates that the anti-MRP1 antibody (Mab)-IR700 conjugate shows higher cellular delivery in multidrug resistant SCLC cells, leading to a stronger photokilling effect and tumor suppression.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2021)
Article
Nanoscience & Nanotechnology
Fengmei Chao, Yang Zhang, Lei Lv, Yaqin Wei, Xiaoyan Dou, Na Chang, Qiyi Yi, Ming Li
Summary: By transcriptome sequencing, differentially expressed circRNAs were screened in chemoresistant and chemosensitive small cell lung cancer (SCLC) cells, and circSH3PXD2A was identified as significantly downregulated. In vivo and in vitro experiments demonstrated that circSH3PXD2A inhibits chemoresistance in SCLC through the miR-375-3p/YAP1 axis. Additionally, EVs-derived circSH3PXD2A may serve as a predictive biomarker for DDP-resistant SCLC patients.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2023)
Article
Multidisciplinary Sciences
Nathan Farrokhian, Jeff Maltas, Mina Dinh, Arda Durmaz, Patrick Ellsworth, Masahiro Hitomi, Erin McClure, Andriy Marusyk, Artem Kaznatcheev, Jacob G. Scott
Summary: In this study, the frequency-dependent interactions between a gefitinib-resistant non-small cell lung cancer population and its sensitive ancestor were measured experimentally. The cost of resistance was found to be insufficient in predicting competitive exclusion, and frequency-dependent growth rate measurements were necessary. Simulations showed that ecological growth effects can influence the predicted extinction time.
Article
Cell Biology
Chenlong Li, Hongshan Zheng, Jinsheng Xiong, Yuxin Huang, Haoyang Li, Hua Jin, Siqi Ai, Yingjie Wang, Tianqi Su, Guiyin Sun, Xu Xiao, Tianjiao Fu, Yujie Wang, Xin Gao, Peng Liang
Summary: This study investigates the role of miR-596-3p in brain metastasis of NSCLC. The results reveal that miR-596-3p inhibits the invasion of cancer cells and permeability of the blood brain barrier by modulating the YAP1-IL8 network. The findings suggest that miR-596-3p may serve as a potential therapeutic target for brain metastasis in NSCLC.
CELL DEATH & DISEASE
(2022)
Article
Oncology
Kui Yang, Yang Zhao, Yonghao Du, Ruixiang Tang
Summary: This study firstly reported the expression of key Hippo pathway proteins in SCLC patients and identified that CD133 may be controlled by the expression of YAP1 in the Hippo pathway, which may be associated with the radiation resistance of SCLC.
JOURNAL OF ONCOLOGY
(2021)
Article
Cell Biology
Tong Yu, Yanyan Liu, Junwen Xue, Xiang Sun, Di Zhu, Lu Ma, Yingying Guo, Tongzhu Jin, Huiying Cao, Yingzhun Chen, Tong Zhu, Xuelian Li, Haihai Liang, Zhimin Du, Hongli Shan
Summary: This study found that Gankyrin is upregulated in non-small cell lung cancer (NSCLC) and plays a role in promoting cancer progression through the regulation of YAP1 and glycolysis. The inhibition of Gankyrin could potentially be a therapeutic strategy for NSCLC.
CELL DEATH DISCOVERY
(2022)
Review
Oncology
Elena Corral de la Fuente, Maria Eugenia Olmedo Garcia, Ana Gomez Rueda, Yolanda Lage, Pilar Garrido
Summary: KRAS is the most frequently altered oncogene in NSCLC, and its mutant tumors have distinct biology and response to treatment, which makes developing effective drugs challenging. The recent discovery of a new pocket in KRAS G12C has led to the development of inhibitors as a new treatment option. However, resistance to targeted KRAS G12C inhibitors is also a concern, and research is ongoing to understand the mechanisms and find suitable drugs. Co-mutations and combination therapy are also areas of interest.
FRONTIERS IN ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Jun W. Kim, Julie H. Ko, Julien Sage
Summary: This study investigates the role of tumor heterogeneity in small-cell lung cancer (SCLC) and identifies DLL3 as a biomarker of neuroendocrine state and a regulator of cell-cell interactions in SCLC.
Article
Cell Biology
Haruki Saito, Yuki Tenjin, Tatsuya Yamada, Shinji Kudoh, Noritaka Kudo, Mune Sanada, Younosuke Sato, Akira Matsuo, Yorihisa Orita, Takaaki Ito
Summary: This study reveals the important roles of YAP1 in cell proliferation, invasion capacity, drug sensitivity, and neuroendocrine differentiation in small cell lung cancer.
Article
Biochemistry & Molecular Biology
Prabhu Thirusangu, Upasana Ray, Sayantani Sarkar Bhattacharya, Derek B. Oien, Ling Jin, Julie Staub, Nagarajan Kannan, Julian R. Molina, Viji Shridhar
Summary: PFKFB3 is an important enzyme in glycolysis that is overexpressed in many human cancers. Its high expression promotes glycolysis and survival in cancer stem cells, while inhibition of PFKFB3 can reduce proliferation, spheroid formation, chemotherapy resistance, and invasion/migration in SCLC cells.
Review
Oncology
Juan Bautista Blaquier, Andres Felipe Cardona, Gonzalo Recondo
Summary: KRAS(G12C) inhibitors show promising anti-tumor activity in non-small cell lung cancer patients, but resistance mechanisms, including novel KRAS mutations, may limit their effectiveness in the long term. Further research is needed to develop strategies to overcome or prevent resistance in clinical settings.
FRONTIERS IN ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Hiroki Izumi, Shingo Matsumoto, Jie Liu, Kosuke Tanaka, Shunta Mori, Kumiko Hayashi, Shogo Kumagai, Yuji Shibata, Takuma Hayashida, Kana Watanabe, Tatsuro Fukuhara, Takaya Ikeda, Kiyotaka Yoh, Terufumi Kato, Kazumi Nishino, Atsushi Nakamura, Ichiro Nakachi, Shoichi Kuyama, Naoki Furuya, Jun Sakakibara-Konishi, Isamu Okamoto, Kageaki Taima, Noriyuki Ebi, Haruko Daga, Akira Yamasaki, Masahiro Kodani, Hibiki Udagawa, Keisuke Kirita, Yoshitaka Zenke, Kaname Nosaki, Eri Sugiyama, Tetsuya Sakai, Tokiko Nakai, Genichiro Ishii, Seiji Niho, Atsushi Ohtsu, Susumu S. Kobayashi, Koichi Goto
Summary: Lung cancer is a highly aggressive tumor type, and targeted therapies based on oncogenic drivers have greatly improved outcomes for patients with non-small-cell lung cancer (NSCLC). However, a significant percentage of lung adenocarcinoma cases lack known oncogenic drivers, and the identification of the CLIP1-LTK fusion as a potential target in NSCLC represents a novel finding with therapeutic implications.